Name: Eui Kyu Chie · Radiotherapy for breast cancer patients treated with preoperative chemotherapy followed by surgery. 2007/05/11 Korean Society for Radiation Oncology Symposium,

Curriculum Vitae

as of Aug 1, 2019

Name : Eui Kyu Chie, MD, PhD

Present Title and Affiliation

Professor

Department of Radiation Oncology

Seoul National University College of Medicine

Seoul National University Hospital

Contact Information

Office address:

Department of Radiation Oncology, Seoul National University Hospital

101 Daehak-ro, Jongno-gu, Seoul, Korea

Tel: 82-2-2072-3705

Fax: 82-2-765-3317

e-mail: [email protected]

Licensure and Certification

1995 Medical License, Korea No. 55831

2000 Therapeutic Radiology & Oncology Board, Korea No. 286

Education

89 03 - 91 02 Undergraduate, College of Liberal Arts and Science., Seoul National University

91 03 - 95 02 M.D., Seoul National University College of Medicine

97 03 - 99 08 M.S., Seoul National University Graduate School

In vivo and in vitro confirmation of dose homogeneity in total body irradiation

with thermoluminescent dosimeter

04 03 - 11 02 Ph.D., Seoul National University Graduate School

In vitro and in vivo radiosensitizing effect of valproic acid on fractionated

irradiation in U87MG and A549 tumors

mailto:[email protected]

Training

95 03 – 96 02 Rotational Internship


96 03 – 00 02 Residency

Department of Therapeutic Radiology, Seoul National University Hospital

02 04 – 03 04 Attending Physician

Proton Therapy Center, National Cancer Center

03 05 – 04 03 Clinical Instructor

Department of Radiation Oncology, Seoul National University Hospital

11 01 – 11 01 Visiting Observer

Department of Radiation Oncology, Henry Ford Hospital & Medical Centers

11 01 – 11 02 Visiting Observer

Department of Radiation Oncology, Stanford University Medical Center

14 09 – 16 02 Post-doctoral Research Fellow / Visiting Scholar

Department of Translational Hematology & Oncology, Lerner Research Institute,

Cleveland Clinic Foundation

Faculty Appointments

04 04 – 11 02 Assistant Clinical Professor



11 03 – 16 08 Associate Professor




16 09 – Professor




Professional Society Activities

04 10 – 13 09

Member

Scientific Committee, Korean Society for Radiation Oncology

04 10 – 11 09 Member

Editorial Board, Korean Society for Radiation Oncology

04 10 – 09 09 Member

Quality Assurance Committee, Korean Society for Radiation Oncology

05 11 – 08 05 Member

Scientific Committee, Korean Association of Clinical Oncology

06 06 – 08 06 Secretary

Information Technology Committee, Korean Cancer Association

07 10 – 11 09 Member

Clinical Research Committee, Korean Society for Radiation Oncology

07 10 – 09 09 Member

Medical Terminology Committee, Korean Society for Radiation Oncology

08 06 – 10 05 Secretary

Multidisciplinary Committee, Korean Association of Clinical Oncology

09 10 – 11 09 Secretary

Scientific Committee, Korean Society for Radiation Oncology

10 05 – 14 05 Member

Scientific Committee, Korean Association of Clinical Oncology

16 03 – 18 02 Secretary of Medical Affairs

Korean Association for Radiation Protection

16 08 – Associate editor

Cancer Research & Treatment

16 08 – 18 06 Member

Scientific Committee, Korean Cancer Association

16 08 – 18 06 Member

General Affairs Committee, Korean Cancer Association

17 09 – Secretary

International Congress Support Committee, 15th International Congress of

International Radiation Protection Association

17 10 – Director of Medical and Health Insurance Affairs

Korean Society for Radiation Oncology

18 03 – General Secretary

Korean Association for Radiation Protection

Administrative Activities

99 03 – 99 10 Resident Representative

OCS Project Task Force Team, Seoul National University Hospital

03 05 – 03 10 Department of Radiation Oncology Representative

EMR Project Task Force Team, Seoul National University Hospital

05 03 – 10 08 Consultant for EMR

Medical Information Center, Seoul National University Hospital

09 06 – 10 06 Project Leader, Billing System Upgrade Project


10 09 – 14 08 Director, Division of Research and Development for Medical Information


11 04 – 11 10 Project Leader, Smart Bestcare: Mobile EMR Solution Development Project


12 03 – 12 10 Project Leader, System Performance Index Upgrade Project


12 06 – 14 06 Vice Director

Department of Education and Research, Seoul National University Hospital

12 08 – 14 08

18 09 –

Expert Secretary

Institutional Review Board, Seoul National University Hospital

12 09 – 14 08

16 07 –

Board member

Multidisciplinary Review Board, Seoul National University Hospital

16 07 – Director of Research & Cooperation

Seoul National University Cancer Hospital

18 01 – Director of Research Planning

Medical Research Center, Seoul National University

19 07 – Deputy Chief

Office of Planning & Coordination, Seoul National University Hospital

Honors and Awards

1. 1999/10/09 Best Poster Award

Korean Society for Therapeutic Radiology & Oncology

Clinical significance of irradiated volume in low-dose brachytherapy for patients with uterine cervix

cancer

2. 2001/11/05 Certificate of Commendation

Governor of Gyeonggi Province

Infectious disease termination & measles vaccination project

3. 2007/05/23 Certificate of Commendation

The 30th Infantry Division Commander

2007 Mobilization Training

4. 2009 2/6 Certificate of Commendation

President of Seoul National University Hospital

Development and implementation of RT PACS Program

5. 2010 5/14 Outstanding Reviewer Award

Korean Society for Therapeutic Radiology & Oncology

6. 2010 6/12 Asia-Pacific Journal of Clinical Oncology Publication Award

Korean Association of Clinical Oncology

Results of breast conservative therapy for multifocal or multicentric breast cancers.

7. 2011 6/30 Ministry of Education, Science and Technology Award

Korea Radioisotope Association

Development and implementation of RT PACS Program

8. 2011 11/4 Hanmi Outstanding Presentation Award


Ramosetron versus ondansetron for radiotherapy induced nausea and vomiting: A preliminary

analysis of phase III prospective randomized trial for gastrointestinal malignancies.

9. 2013 11/1 Outstanding Oral Presentation Award


The impact of the margin status in the neoadjuvant chemoradiation of rectal cancer: A preliminary

analysis of multicenter, retrospective study (KROG 13-01)

10. 2013 11/28 Outstanding Reviewer of Institutional Review Board Award

Seoul National University College of Medicine & Seoul National University Hospital

11. 2015 6/29 The 5th Korean Cancer Association Merck-Serono Cancer Academic Award

Impact on loco-regional control of radiochemotherapeutic sequence and time to initiation of

adjuvant treatment in stage II/III rectal cancer patients treated with postoperative concurrent

radiochemotherapy

List of publications, book chapters

1. Ha SW, Chie EK. Radiotherapy in pancreaticobiliary malignancies. Park YH, Kim SW, Lee KW, Seo

KS editors, Hepato-Biliary-Pancreatic Surgery, 2nd ed. Seoul. Medrang, 2006. ISBN 89-85348-66-3

2. Jeong JW, Yoon JH, Lee JM, Chie EK. Loco-regional management in hepatocellular carcinoma. Song

IS, Jeong HC, Kim JS, Lee HS, Yoon JH, Yoon YB, Kim YT, Ryu JG editors, Gastrointestinal Disease,

3rd ed. Seoul. Ilchokak, 2011. ISBN 978-89-337-0601-5 93510

3. Chie EK. Radiotherapy in pancreatic cancer. Song IS, Jeong HC, Kim JS, Lee HS, Yoon JH, Yoon YB,

Kim YT, Ryu JG editors, Gastrointestinal Disease, 3rd ed. Seoul. Ilchokak, 2011. ISBN 978-89-337-

0601-5 93510

4. Jeong SY, Chie EK, Oh DY. Anal cancer. Park JG editor. Coloproctotology 4th ed. Seoul. Ilchokak,

2012. ISBN 978-89-85348-96-6 93510

5. Kim YT, Jang JY, Chie EK, Han SW. Biliary malignancy. Park JG, Bang YJ, Ha SW editors. Oncology,

revised. Seoul. Ilchokak, 2012. ISBN 978-89-337-0632-9 93510

6. Jeong SY, Chie EK, Oh DY. Anal cancer. Park JG, Bang YJ, Ha SW editors. Oncology, revised. Seoul.

Ilchokak, 2012. ISBN 978-89-337-0632-9 93510

7. Chie EK. Radiotherapy in pancreaticobiliary malignancies. Park YH, Kim SW, Lee KW, Seo KS editors,

Hepato-Biliary-Pancreatic Surgery, 3rd ed. Seoul. Medrang, 2013. ISBN 978-89-85348-96-6 93510

8. Jeong JW, Yoon JH, You SJ, Lee JM, Chie EK. Loco-regional management in hepatocellular carcinoma.

Yoon JH, Kim JS, Ryu JG editors, Gastrointestinal Disease, 4th ed. Seoul. Ilchokak, 2016. ISBN 978-

89-337-0712-8 94510

9. Chie EK. Radiotherapy in pancreatic cancer. Yoon JH, Kim JS, Ryu JG editors, Gastrointestinal Disease,

4th ed. Seoul. Ilchokak, 2016. ISBN 978-89-337-0712-8 94510

10. Chie EK. Radiotherapy in pancreaticobiliary malignancies. Park YH, Kim SW, Lee KW, Seo KS editors,

Hepato-Biliary-Pancreatic Surgery, 4th ed. Seoul. Medrang, 2019. ISBN 978-89-85348-28-7 93510

Representative Invited Lectures

1. Early anal cancer, what should we do? 2005/04/27. Korean Cancer Study Group Meeting, Seoul,

Korea

2. Changing radiotherapy paradigm with progress in imaging. 2005/07/08 The 2nd Institute of

Radiation Medicine Seminar, Seoul, Korea

3. Radiation protection of patient and staff. 2006/07/04 The 1st KFDA(Korean Food and Drug

Administration) Training for quality assurance on radiotherapy for asia and pacific countries, Seoul,

Korea

4. Radiotherapy for breast cancer patients treated with preoperative chemotherapy followed by

surgery. 2007/05/11 Korean Society for Radiation Oncology Symposium, Jeju, Korea

5. Recent updates of chemoradiotherapy in rectal cancer. 2007/06/16 The 4th Korean Association of

Clinical Oncology Symposium, Seoul, Korea

6. Adjuvant radiotherapy in pancreatic cancer: Pro. 2007/11/10 The 5th Korean Association of Clinical

Oncology Symposium, Seoul, Korea

7. Radiotherapy in pancreaticobiliary cancer. 2007/12/15 The 4th Korean Society of Gastrointestinal

Cancer Symposium, Busan, Korea

8. Past, present, and future of radiotherapy. 2008/05/02 The 32nd Annual Meeting of Korean Medical

Association: Centennial Memorial Meeting, Seoul, Korea

9. Linac-based radiotherapy for hepatocellular carcinoma. 2008/05/16 Korean Liver Society Annual

Meeting Postgraduate Course, Daegu, Korea

10. Guidelines for radiotherapy after breast conserving surgery: Invasive breast cancer. 2008/06/21 The

24th Annual Meeting of Korean Breast Cancer Society, Jeju, Korea

11. Phase III Randomized Trial of Whole Breast Radiotherapy vs. Whole Breast Radiotherapy Plus Tumor

Bed Boost after Conservative Surgery for Ductal Carcinoma In Situ: KROG 08-05. 2008/07/26 2008

KOSTRO Clinical Research Committee Workshop, Seoul, Korea

12. Optimal time of the radiation therapy after breast conserving surgery. 2008/09/20 2008 International

Oncoplastic Breast Surgery Symposium, Daegu, Korea

13. Current clinical trials on locoregional treatment. 2009/07/18 Korean Society for Radiation Oncology

Breast Radiotherapy Workshop, Seoul, Korea

14. Radiotherapy in breast cancer. 2009/11/08 Seoul National University Hospital CME Academy, Seoul,

Korea

15. Discussion to create Korean edition 2009 Guidelines. 2009/12/04 2nd NCCN-Korea Cancer Guideline

Meeting, Seoul, Korea

16. Management of regional recurrence in breast cancer. 2010/05/29 The 26th Annual Meeting of

Korean Breast Cancer Society, Jeju, Korea

17. Radiation therapy for CNS metastases of breast cancer. 2010/10/16 The 13th Korean Association of

Clinical Oncology Consensus Conference, Seoul, Korea

18. Coping with the margin: A radiation oncologist’s perspective. 2010/11/19 The 15th Annual Meeting

of Korean Cancer Association, Seoul, Korea

19. Personalized care in radiation oncology: No longer one for all. 2011/04/10 Commemorative

Symposium for the opening of Seoul National University Cancer Hospital in conjunction with the

20th International Cancer Symposium of Seoul national University Cancer Research Institute, Seoul,

Korea

20. Directing policies to facilitate multidisciplinary approach. 2011/11/11 Policy forum for

multidisciplinary approach in oncology. National Assembly, Seoul, Korea

21. Development of smartphone application at SNUH. 2011/11/11 The 27th Annual meeting of Korean

Society of Medical Informatics. Incheon, Korea

22. Radiotherapy for hepatocellular carcinoma: Treating the moving target. 2011/12/03 Asia-Pacific

Association for Study of Liver 2nd Hepatocellular Conference. Jeju, Korea

23. Radioisotope application in radiotherapy. 2012/05/11 2012 Hanaro symposium, Daejeon, Korea

24. Radiological indications and modalities for colorectal cancer. 2012/06/16 The 9th Korean Society of

Gastrointestinal Cancer Symposium. Seoul, Korea

25. Advances in radiotherapy: what we “CAN” do in the year 2012. 2012/06/21 International scientific

and practical conference “Oncology – modern aspects and the priority directions” devoted to the

60th anniversary of the Oncological Center of Astana City. Astana, Kazakhstan

26. Role of radiotherapy in the management of rectal cancer: an Overview with some updates.

2012/06/22 International scientific and practical conference “Oncology – modern aspects and the

priority directions” devoted to the 60th anniversary of the Oncological Center of Astana City. Astana,

Kazakhstan

27. Present of KOSRO (Korean Society for Radiation Oncology). 2012/10/12 The 30th Annual Meeting

of Korean Society for Radiation Oncology. Seoul, Korea

28. Controversial issues of neoadjuvant treatment in pancreatic cancer: Optimal regimens and

perioperative evaluation of treatment efficacy. 2012 11/29 – 12/1 The 37th Annual Meeting of Korean

Association of Hepato-Biliary and Pancreas Surgery. Seoul, Korea

29. Progress in radiotherapy: Image-guided radiotherapy. 2013/02/06 Uijeongbu St. Mary’s Hospital

Commemorate Seminar. Uijeongbu, Korea

30. Basic radiation biology from clinician’s perspective. 2013/03/15 IAEA Program of Action for Cancer

Therapy & Training Course Fellowship Lecture. Korean Cancer Center Hospital, Seoul, Korea

31. Radiation therapy for extrahepatic metastases from hepatocellular carcinoma. 2013/04/06 The 2nd

Mongolian-Korean Liver Cancer Study Group Symposium. Ulan Bator, Mongolia

32. How to define the tumor bed after oncoplastic breast surgery? 2013/05/25 2013 Trans-Asia

Symposium of Intra-Operative Radiotherapy & Surgical Techniques. Taipei, Taiwan

33. Multi-institutional Cooperative Group Clinical Trials: KROG, Effort of Korean Radiation Oncologists.

2013/11/19 Forum for Nuclear Cooperation in Asia FY 2013 Workshop on Radiation Oncology,

Seoul, Korea

34. Medical training program at Seoul National University Hospital. 2013/11/25 – 11/28 Medical Korea:

Introductory seminar on medical training program in Korea for Saudi doctors. Damman, Jeddah,

and Riyad, Saudi Arabia

35. What’s after preoperative chemoradiotherapy? 2013/12/14 ESMO Asia CME Partner Centre:

Colorectal Program. Seoul, Korea

36. The significance of resection margin after preoperative chemoradiotherapy in rectal cancer.

2014/02/28 2014 KROG (Korea Radiation Oncology Group) Rectal Cancer Division Symposium. Seoul,

Korea.

37. Implementation experience in Radiation Oncology. 2014/03/28 2014 Conference on Teaching. Seoul

National University Center for Teaching & Learning. Seoul, Korea

38. Introduction to radiogenomics. 2016/05/13 The 34th Annual Meeting of the Korean Society for

Radiation Oncology. Gangneung, Korea

39. Liver IGRT experiences at SNUH, Which machine or technique has an advantage for liver IGRT?

2016/10/08 The 2nd liver IGRT practicum. Seoul, Korea.

40. When & why “I” choose MRDian, focusing on the moving target. 2016/10/21 2016 Asan

Radiosurgery Symposium. Seoul, Korea.

41. Precision medicine in radiation oncology, from physics to biology? 2016/10/28 The 15th Seoul

Radiation Oncology Symposium. Seoul, Korea.

42. State of the art 1, radiogenomics. 2016/12/07 ASEAN Trainer Training Courses on Radiation

Treatment. Korea Institute of Radiological and Medical Sciences, Seoul, Korea.

43. Advances in radiation oncology. 2017/01/21 The 9th workshop of Korean Cancer Association. Seoul,

Korea.

44. Radiotherapeutic strategies for organ preservation. 2017/02/18 Seoul Multidisciplinary Treatment

Symposium for Colorectal Cancer 2017. Bundang, Gyonggi, Korea.

45. MR guided SABR, promises and limitations. 2017/03/17 The 12th Annual Meeting of the Korean

Radiosurgery Society. Seoul, Korea.

46. Tailored radiotherapy based on radiosensitivity prediction in rectal cancer. 2017/06/22 24th Asia

Pacific Cancer Conference. Seoul, Korea.

47. Trials – Prediction for response of preoperative chemoradiation. 2017/07/01 2017 Updates for

Colorectal Cancer, Guideline & Trials. National Cancer Center, Goyang, Gyonggi, Korea.

48. Predicting response to radiation therapy and treatment outcomes. 2017/10/13 The 35th Annual

Meeting of the Korean Society for Radiation Oncology. Seoul, Korea.

49. Ongoing evolution in radiotherapy for rectal cancer. 2017/10/27 The 73rd Korean Congress of

Radiology (KCR 2017). Seoul, Korea.

50. Revisiting the role of radiotherapy in the management of CNS metastases. 2017/11/03 The 5th

Meeting of the Asian Leksell Gamma Knife Society. Jeju, Korea.

51. Management of gastric cancer. A perspective of radiation oncologist from ‘endemic’ area.

2017/11/30 Invited lecture, Department of Radiation Oncology, Washington University. St Louis,

MO USA.

52. Radiosensitivity prediction for precision radiation oncology. 2017/12/08 Humanitas International

Cancer Symposium. Seoul, Korea.

53. National Health Insurance in Radiation Oncology, Where are we now? 2018/05/11 2018 Annual

Spring Symposium of Korean Society for Radiation Oncology. Jeju, Korea.

54. Optimal radiotherapy in rectal cancer. 2018/05/18 The 16th Annual Symposium & General Assembly,

Korean Society of Medical Oncology. Seoul, Korea

55. Management of gastric cancer: Perspective of a Radiation Oncologist. 2018/07/11 2018 Nuclear

Medicine Workshop (KOICA/TEIN). Seoul, Korea

56. Radiotherapy for colorectal cancer & metastases. 2018/08/18 The 18th Korean Spine Oncology

Research Society Symposium. Seongnam, Korea

57. Expert panel case discussion, 2018/08/25 The 3rd Liver IGRT Practicuum, Seoul, Korea

58. Complications of radiotherapy in colorectal cancer, 2018/10/19 The 12th Annual Meeting of the

Society of Gastrointestinal Intervention, Nanjing, China

59. ‘Precision’ in radiation oncology. 2019/05/17 2019 Korean Society of Radiation Biology Spring

Conference. Busan, Korea

60. Recent Updates in GI Radiation Oncology. 2019/06/01 The 3rd Korean Society of Gastrointestinal

Cancer Oncology Nursing Symposium. Seoul, Korea

61. Role of radiotherapy in pancreatic cancer. 2019/07/14 Seoul National University Cancer Hospital

Training Course for Practicing Clinicians. Seoul, Korea

Full list of publications, journals

1. Shin KH, Huh SJ, Chie EK, Choi DR, Lim DH, Kim MK, Lee KC, Kim DY, Ahn YC. Analysis of correlation

between rectal complications and rectal dose following high dose rate intracavitary radiotherapy in

patients with uterine cervix cancer: in vivo dosimetric analysis. Radiat Med 1999;17(4):289-293 (Co-

author)

2. Kim IH, Park SW, Chie EK, Ha SW, Park CI. Efficacy and optimal condition of radiotherapy for

metastatic epidural cord compression. J Korean Cancer Assoc 1999;31(5):1074-1080 (Co-author)

3. Hong S, Wu HG, Chie EK, Bang YJ, Heo DS, Kim KH, Sung MW, Park CI. Neoadjuvant chemotherapy

and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal

carcinoma. Int J Radiat Oncol Biol Phys 1999;45(4):901-905 (Co-author)

4. Chie EK, Park SW, Kang WS, Kim IH. In vivo and in vitro confirmation of dose homogeneity in total

body irradiation with thermoluminescent dosimeter. J Korean Soc Ther Radiol 1999;17(4):321-328

(First author)

5. Chie EK, Lee MM, Wu HG. Radiation exposure of the operator in intracoronary radiotherapy using

Re-188. J Korean Assoc Rad Protect 2000;25(4):191-195 (First author)

6. Chie EK, Chae IH, Lee MM, Wu HG. Exposure of the operator to ionizing radiation during

intracoronary radiotherapy. J Interv Cardiol 2002;15(1):15-18 (First author)

7. Chie EK, Ha SW, Park JG, Bang YJ, Heo DS, Kim NK. Treatment results in anal cancer: Non-operative

treatment versus operative treatment. J Korean Soc Ther Radiol 2002;20(1):62-67 (First author)

8. Kim BK, Chie EK, Huh SN, Lee HK, Ha SW. Clinical application of in vivo dosimetry system in

radiotherapy of pelvis. J Korean Assoc Rad Protect 2002;27(1):37-49 (Co-author)

9. Yun HG, Chie EK, Huh SN, Lee HG, Wu HG, Shin KC, Ha SW. Transmission dose estimation algorithm

for tissue deficit. J Korean Soc Ther Radiol 2002;20(2):186-192 (Co-author)

10. Yun HG, Chie EK, Huh SN, Lee HG, Wu HG, Shin KC, Kim S, Ha SW. Transmission dose estimation

algorithm for in vivo dosimetry. J Korean Assoc Rad Protect 2002;27(3):147-154 (Co-author)

11. Yun HG, Chie EK, Huh SN, Lee HG, Wu HG, Shin KC, Kim S, Ha SW. Transmission dose estimation

algorithm for irregularly shaped radiation field. J Korean Soc Ther Radiol 2002;20(3):274-282 (Co-

author)

12. Hong S, Chie EK, Park SW, Kim IH, Ha SW, Park CI. Outcome of LINAC radiosurgery for a cavernous

angioma. J Korean Soc Ther Radiol 2003;21(2):107-111 (Co-author)

13. Kim HJ, Hong S, Kim S, Kim JH, Chie EK, Kim IH, Park CI, Ha SW, Wu HG, Kim DG, Kang WS. Efficacy

of whole brain radiotherapy combined with fractionated stereotactic radiotherapy in metastatic brain

tumors, and prognostic factors. Radiat Med 2003;21(4):155-160 (Co-author)

14. Kim IH, Chie EK, Park CI. Reduction of patient dose in radiation therapy for brain tumors by using

2-dimensional vertex or oblique vertex beam technique. J Korean Assoc Rad Protect 2003;28(3):225-

231 (Co-author)

15. Oh DH, Chie EK, Kim IH. Web-based data collection system for patterns of care study of radiation

oncology. J Kor Soc Med Informatics 2003;9(4):423-429 (Co-author)

16. Kim IH, Chie EK, Oh DH, Suh CO, Kim JH, Ahn YC, Hur WJ, Chung WK, Choi DH, Lee JW. A web-

based 'Patterns of Care Study' system for clinical radiation oncology in Korea: Development,

launching, and characteristics. J Kor Soc Ther Radiol Oncol 2003;21(4):291-298 (Co-author)

17. Chie EK, Wu HG, Heo DS, Bang YJ, Kim NK, Ha SW. Neoadjuvant chemotherapy followed by

radiotherapy in epidermoid carcinoma of anus. Tumori 2004;90(3):299-302 (First author)

18. Lee SH, Kim TH, Chie, EK, Im HS, Im ES, Ryu JS, Jung YS, Park SY, Kim JY, Pyo HR, Shin KH, Kim DY,

Cho KH. Evaluation of xerostomia following intensity modulated radiotherapy (IMRT) for head and

neck cancer patients. J Kor Soc Ther Radiol Oncol 2004;22(2):106-114 (Co-author)

19. Kim JH, Shin JH, Chie EK, Wu HG, Kim JS, Kim IH, Ha SW, Park CI, Kang WS. Trichostatin A, a histone

deacetylase inhibitor, potentiated cytotoxic effect of inonizing radiation in human head and neck

cancer cell lines. J Kor Soc Ther Radiol Oncol 2004;22(2):138-144 (Co-author)

20. Kim K, Chie EK, Kim CW, Kim IH, Park CI. Treatment Outcome of Angiocentric T-cell and NK/T-cell

Lymphoma, Nasal Type: Radiotherapy Versus Chemoradiotherapy. Jpn J Clin Oncol 2005;35(1):1-5

(Co-author)

21. Chie EK, Park JP, Huh SN, Hong S, Park SW, Kim IA, Wu HG, Kim JS, Kang WS, Kim IH, Ha SW, Park

CI. Carbon fiber as material for radiation fixation device: A comparative study with acrylic. J Korean

Assoc Rad Protect 2005;30(1):1-7 (First author)

22. Kim IA, Kim JH, Shin JH, Kim IH, Kim JS, Wu HG, Chie EK, Kim YH, Kim BK, Hong S, Park SW, Ha SW,

Park CI. A histone deacetylase inhibitor, Trichostatin A, enhances radiosensitivity by abrogating G2/M

arrest in human carcinoma cells. Cancer Res Treat 2005;37(2):122-128 (Co-author)

23. Kim IA, Kim JH, Shin JH, Kim IH, Kim JS, Wu HG, Chie EK, Kim YH, Kim BK, Hong S, Ha SW, Park CI.

Leptomycin B increases radiosensitization by Trichostatin A in HeLa cells. J Kor Soc Ther Radiol Oncol

2005;23(2):116-122 (Co-author)

24. Kim TH, Chie EK, Kim DY, Park SY, Cho KH, Jung KH, Kim YH, Sohn DK, Jeong SY, Park JG. Comparison

of the belly board device method and the distended bladder method for reducing irradiated small

bowel volumes in preoperative radiotherapy of rectal cancer patients. Int J Radiat Oncol Biol Phys

2005;62(3):769-775 (Co-first author)

25. Kim K, Chie EK, Wu HG, Kim KH, Sung MH, Heo DS, Park CI. Treatment Outcome of metastatic

carcinoma of cervical lymph node from an unknown primary. J Kor Soc Ther Radiol Oncol

2005;23(3):137-142 (Co-author)

26. Kim K, Kim S, Chie EK, Kim SW, Bang YJ, Ha SW. Postoperative chemoradiotherapy of pancreatic

cancer: What is the appropriate target volume of radiation therapy? Tumori 2005;91(6):493-497 (Co-

author)

27. Yeo I, Kim DY, Kim TH, Shin KH, Chie EK, Park W, Lim DH, Huh SJ, Ahn YC. Contralateral breast dose

reduction using virtual wedge. J Kor Soc Ther Radiol Oncol 2005;23(4):230-235 (Co-author)

28. Shin KH, Kim TH, Cho JK, Kim JY, Park SY, Park SY, Kim DY, Chie EK, Pyo HR, Cho KH. CT-Guided

intracavitary radiotherapy for cervical cancer: Comparison of conventional point A plan with clinical

target volume-based three-dimensional plan using dose-volume parameters. Int J Radiat Oncol Biol

Phys 2006;64(1):197-204 (Co-author)

29. Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, Chie EK, Ha SW, Park CI, Kao GD. Histone deacetylase

inhibitor-mediated radiosensitization of human cancer cells: Class differences and the potential

influence of p53. Clin Cancer Res 2006;12(1):940-949 (Co-author)

30. Kim K, Chie EK, Wu HG, Ha SW, Kim JS, Kim IA, Lee HP. Efficacy of paclitaxel and carboplatin as a

regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol

Oncol 2006;101(3):398-402 (Co-author)

31. Cho W, Huh SN, Chie EK, Ha SW, Park YG, Park JM, Park SW. The evaluation of radiation dose to

embryo/fetus and the design of shielding in the treatment of brain tumors. J Korean Assoc Rad

Protect 2006;31(4):203-210 (Co-author)

32. Keum KC, Shim SJ, Lee IJ, Park W, Lee SW, Shin HS, Chung EJ, Chie EK, Kim IH, Oh DH, Ha SW, Lee

HS, Ahn SJ, Cho MJ, Loh JJK, Lee MZ, Ahn KJ, Park KR, Choi DH, Kim WD, Kim BK, Chun M, Kim JH,

Suh CO. The 1998, 1999 patterns of care study for breast irradiation after mastectomy in Korea. J

Kor Soc Ther Radiol Oncol 2007;25(1):7-15 (Co-author)

33. Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW,

Bang YJ. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had

received doxorubicin and cyclophosphamide followed by paclitaxel as an adjuvant chemotherapy.

BMC Cancer. 2007;7(1):63 (Co-author)

34. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park

IA, Noh DY, Heo DS, Ha SW, Bang YJ. Prognostic impact of clinicopathologic parameters in stage

II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical

features of the triple negative breast cancer. BMC Cancer. 2007;7(1):203 (Co-author)

35. Chie EK, Kim K, Noh DY, Choe KJ, Kim TY, Im SA, Bang YJ, Ha SW. Negative impact of heat exposure

on cosmesis after conservative treatment for breast cancer. Tumori 2007;93(6):591-596 (First author)

36. Chie EK. Radiation Therapy in Pancreatic Cancer. Kor J Gastroenterology 2008;51(2):101-110 (Single

author)

37. Gwak GY, Yoon JH, Chie EK, Chung JW, Lee HS. Successful treatment for hepatocellular carcinoma

with main portal vein tumor thrombi by 3-dimensional conformal radiation therapy combined with

transarterial chemoembolization. Hepatogastroenterology 2008;55(82-83):673-676 (Co-author)

38. Chie EK, Kim K, Choi JW, Jang NY, Han WS, Noh DY, Im SA, Kim TY, Bang YJ, Ha SW. Results of

breast conserving surgery and postoperative radiotherapy for breast cancer. J Kor Soc Ther Radiol

Oncol 2008;26(3):142-148 (First author)

39. Park HC, Choi DH, Ahn SV, Kang JO, Kim ES, Park W, Ahn SD, Yang DS, Yun HG, Chung EJ, Chie EK,

Pyo H, Hong S. Statistical Errors in Papers in the Journal of the Korean Society for Therapeutic

Radiology and Oncology. J Kor Soc Ther Radiol Oncol 2008;26(4):289-294 (Co-author)

40. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Ramosetron for the

prevention of nausea and vomiting during 5-fluorouracil based chemoradiotherapy for pancreatico-

biliary cancer. Jpn J Clin Oncol 2009;39(2):111-115 (Corresponding author)

41. Seong J, Lee IJ, Shim SJ, Lim DH, Kim TH, Kim JH, Jang HS, Kim MS, Chie EK, Kim JH, Nam TK, Lee

HS, Han CJ. A multicenter retrospective cohort study of practice patterns and clinical outcome on

radiotherapy for hepatocellular carcinoma in Korea. Liver International 2009;29(2):147-152 (Co-

author)

42. Choi JW, Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Does adjuvant

radiotherapy suppress the liver regeneration after partial hepatectomy? Int J Radiat Oncol Biol Phys

2009:74(1):67-72 (Corresponding author)

43. Moon S, Kim H, Chie E, Kim J, Park C. Positive impact of radiation dose on disease free survival and

loco-regional control in postoperative radiotherapy for squamous cell carcinoma of esophagus.

Disease of the esophagus 2009:22(4):298-304 (Corresponding author)

44. Chie EK, Shin KH, Kim DY, Kim TH, Kang HS, Lee ES, Cho KH. Radiation pneumonitis after adjuvant

radiotherapy for breast cancer: a volumetric analysis using CT simulator. J Breast Cancer

2009;12(2):73-78 (First author)

45. Lee JH, Kang HC, Chie EK, Kang GH, Park HG, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Effect of

suboptimal chemotherapy on preoperative chemoradiation in rectal cancer. J Kor Soc Ther Radiol

Oncol 2009;27(2):78-83 (Corresponding author)

46. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY,

Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Clinical significance of axillary nodal ratio in stage II/III

breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2009;116(1):153-160

(Co-author)

47. Chie EK, Kim K, Han W, Noh DY, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Results of breast conservative

therapy for multifocal or multicentric breast cancers. Asia-Pacific J Clin Oncol 2009:5(3):200-205 (First

author)

48. Lim KH, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ. Adjuvant concurrent

chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is

better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single

center study. BMC Cancer 2009;9(1):345 (Co-author)

49. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Role of adjuvant

chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys 2009:75(2):436-441

(Corresponding author)

50. Korean Liver Cancer Study Group and National Cancer Center. Practice guidelines for management

of hepatocellular carcinoma 2009. Kor J Hepatology 2009;15(3):391-423 (Co-author)

51. Kim JH, Han W, Moon HG, Ko E, Lee JW, Kim EK, Park IA, Ha SW, Chie EK, Oh SK, Youn YK, Kim SW,

Hwang KT, Noh DY. Factors affecting the ipsilateral breast tumor recurrence after breast conserving

therapy in patients with T1 and T2 tumors. J Breast Cancer 2009;12(4):324-330 (Co-author)

52. Kim HJ, Kim JS, Chie EK, Noh DY, Bang YJ, Ha SW. The sequencing of chemotherapy and radiotherapy

in breast cancer patients after mastectomy. Tumori 2010;96(1):28-33 (Co-author)

53. Kim K, Chie EK, Han W, Noh DY, Park IA, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Prognostic value of

p53 and bcl-2 expression in patients treated with breast conservative therapy. J Korean Med Sci

2010;25(2):235-239 (Co-author)

54. Lim KH, Oh DY, Chie EK, Han W, Im SA, Kim TY, Park IA, Noh DY, Ha SW, Bang YJ. Metaplastic breast

carcinoma: Clinicopatholoic features and prognostic value of triple neagtivity. Jpn J Clin Oncol

2010;40(2):112-118 (Co-author)

55. Kim K, Chie EK, Han W, Noh DY, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Prognostic factors affecting

the outcome of salvage radiotherapy for isolated loco-regional recurrence after mastectomy. Am J

Clin Oncol 2010:33(1):23-27 (Co-author)

56. Ahn SK, Han W, Moon HG, Yu JH, Ko E, Bae JH, Min JW, Kim TY, Im SA, Oh DY, Han SW, Ha SW, Chie

EK, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. The impact of primary tumor resection on the

survival of patients with stage IV breast cancer. J Breast Cancer 2010;13(1):257-263 (Co-author)

57. Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS. HDAC inhibitor-mediated radiosensitization in human

carcinoma cells: a general phenomenon? J Radiat Res 2010;51(3):257-263 (Co-author)

58. Yhim HY, Han SW, Oh DY, Han W, Im SA, Kim TY, Kim YT, Noh DY, Chie EK, Ha SW, Park IA, Bang YJ.

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung

metastases and implications for pulmonary metastasectomy. Cancer 2010;116(12):2890-2901 (Co-

author)

59. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Is duodenal invasion a

relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile

duct cancer? Int J Radiat Oncol Biol Phys 2010;77(4):1186-1190 (Corresponding author)

60. Kwon JH, Kim YJ, Lee KW, Oh DY, Park SY, Kim JH, Chie EK, Kim SW, Im SA, Kim IA, Kim TY, Park IA,

Noh DY, Bang YJ, Ha SW. Triple negativity and young age as prognostic factors in lymph node-

negative invasive ductal carcinoma of 1cm or less. BMC Cancer 2010;10(1):557 (Co-author)

61. Kim K, Chie EK, Kim W, Kim YJ, Yoon JH, Lee HS, Ha SW. Absence of symptom and intact liver

function are positive prognosticators for patients undergoing radiotherapy for lymph node

metastasis from hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010:78(3):729-734


62. Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JW, Park W, Choi DH, Nam H, Kim JS, Cho MJ, Kim JH, Park

JH, Kang MK, Koom WS, Kim JS, Nam TK, Chie EK, Kim JS, Lee KJ. Pathologic complete response of

primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: Long-

term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg

2010:252(6):998-1004 (Co-author)

63. Chie EK, Shin JH, Kim IA, Kim IH. In vivo radiosensitization effect of HDAC inhibitor, SK-7041 on RIF-

1 cell line. J Kor Soc Ther Radiol Oncol 2010;28(4):220-225 (First author)

64. Kim JS, Moon HG, Ahn SK, Min JW, Shin HC, Kim HS, Yeom CK, Ha SH, Chie EK, Han W, Noh DY.

Clinicopathological characteristics and factors affecting recurrence of Ductal Carcinoma In Situ in

Korean women. J Breast Cancer. 2010;13(4):392-397 (Co-author)

65. Choi JW, Kim JW, Seo JW, Chung CK, Kim KH, Kim JH, Kim JH, Chie EK, Cho HJ, Goo JM, Lee HJ,

Wee WR, Nam SM, Lim MS, Kim YA, Yang SH, Jo EM, Hwang MA, Kim WS, Lee EH, Choi SH.

Implementation of consolidated HIS: improving quality and efficiency of healthcare. Healthcare

Informatics Research 2010;16(4):299-304 (Co-author)

66. Kim K, Chie EK, Han W, Noh DY, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Age less than 40 years is

an independent prognostic factor predicting inferior overall survival in patients treated with breast

conservative therapy. Breast J 2011;1:75-78 (Corresponding author)

67. Kim H, Han W, Moon HG, Min J, Ahn SK, Kim TY, Im SA, Oh DY, Han SW, Chie EK, Ha SW, Noh DY.

The value of preoperative staging chest computed tomography to detect asymptomatic lung and

liver metastasis in patients with primary breast carcinoma. Breast Cancer Res Treat 2011;126(3):637-

641 (Co-author)

68. Lee YG, Han SW, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ. Diagnostic

performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract

cancer after curative resection. BMC Cancer 2011;11(1):188 (Co-author)

69. Kim K, Chie EK, Han W, Noh DY, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Concurrent versus sequential

administration of CMF chemotherapy and radiotherapy after breast conserving surgery in early

breast cancer. Tumori 2011;97(3):280-285 (Corresponding author)

70. Kim K, Chie EK, Han W, Noh DY, Ha SW. Impact of delayed radiotherapy on local control in node-

negative breast cancer patients treated with breast conserving surgery and adjuvant radiotherapy

without chemotherapy. Tumori 2011;97(3):341-344 (Corresponding author)

71. Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL, Ha SW. High survivin expression as a

predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int

J Colorectal Dis 2011;26(8):1019-1023 (Co-author)

72. Kim S, Kim K, Chie EK, Kim SW, Bang YJ, Ha SW. Treatment outcomes and prognostic factors of

gallbladder cancer patients after postoperative radiation therapy. Kor J Hepatobiliary Pancreat Surg.

2011;15(3):152-156 (Co-author)

73. Park HJ, Shin KH, Cho KH, Park IH, Lee KS, Ro J, Jung SY, Lee S, Kim SW, Kang HS, Chie EK, Ha SW.

Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with

neoadjuvant chemotherapy, surgery, and radiotherapy. Int J Radiat Oncol Biol Phys 2011;81(5):e689-

695 (Co-author)

74. Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW,

Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW. Clinical outcome of central nervous system

metastases from breast cancer: differences in survival depending on systemic treatment. J

Neurooncol 2012;106(2):303-313 (Co-author)

75. Park JM, Kim JI, Choi CH, Chie EK, Kim IH, Ye SJ. Photon energy-modulated radiotherapy: Monte

Carlo simulation and treatment planning study. Med Physics 2012;39(3):1265-1277 (Co-author)

76. Kim HJ, Kim JH, Chie EK, Park DY, Kim IA, Kim IH. DNMT (DNA methyltransferase) inhibitors

radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 2012;7(1):39 (Co-

author)

77. Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Adjuvant

chemoradiotherapy after curative resection for extrahepatic biliary tract cancer: a long-term single

center experience. Am J Clin Oncol 2012:35(2):136-140 (Corresponding author)

78. Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Postoperative

chemoradiotherapy for gallbladder cancer. Strahlenther Onkol. 2012;188(5):388-394 (Corresponding

author)

79. Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Prognostic

significance of tumor location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.

Clinical and Translational Oncology 2012;14(5):391-395 (Corresponding author)

80. Park JM, Kim K, Chie EK, Choi CH, Ye SJ, Ha SW. RapidArc® vs intensity-modulated radiation therapy

for hepatocellular carcinoma: a comparative planning study. Br J Radiol 2012;85(1015):e323-329 (Co-

author)

81. Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Distant metastasis

risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation

for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2012;;84(1):81-87 (Corresponding

author)

82. Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB. Phase II clinical

trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by

concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer

Chemother Pharmacol 2012;70(3):381-389 (Co-author)

83. Koom WS, Ahn SD, Song SY, Lee CG, Moon SH, Chie EK, Jang HS, Oh YT, Lee HS, Keum KC.

Nutritional status of patients treated with radiotherapy as determined by subjective global

assessment. Radiat Oncol J. 2012;30(3):132-139 (Co-author)

84. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Role of adjuvant

chemoradiotherapy for duodenal cancer: A single center experience. Am J Clin Oncol 2012;35(6):533-

536 (Corresponding author)

85. Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW. Molecular biomarkers in extrahepatic bile duct

cancer patients undergoing chemoradiotherapy for gross residual disease after surgery. Radiat Oncol

J. 2012;30(4):213-217 (Co-author)

86. Song SH, Chie EK, Kim K, Lee HJ, Yang HK, Han SW, Oh DY, Im SA, Bang YJ, Ha SW. Postoperative

chemoradiotherapy in high risk locally advanced gastric cancer. Radiat Oncol J. 2012;30(4):213-217


87. Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW.

CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. World J Gastroenterol

2013;19(9):1438-1443 (Corresponding author)

88. Park JH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kang GH, Chie EK, Ha SW, Jeong SY, Park KJ, Park

JG, Kim TY. The beneficial effect of palliative resection in metastatic colorectal cancer. Br J Cancer

2013;108(7):1425-1431 (Co-author)

89. Park HJ, Kim HJ, Chie EK, Kang CH, Kim YT. The influence of circumferential resection margin status

on loco-regional recurrence in esophageal squamous cell carcinoma. J Surg Oncol. 2013;107(7):762-

766 (Co-author)

90. Kim MY, Cho N, Koo HR, Yun BL, Bae MS, Chie EK, Moon WK. Predicting local recurrence following

breast-conserving treatment: parenchymal signal enhancement ratio (SER) around the tumor on

preoperative MRI. Acta Radiologica 2013;54(7):731-738 (Co-author)

91. Eom KY, Chie EK, Kim K, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Impact

of dose-volumetric parameters on the development of diabetes mellitus in patients treated with

postoperative chemoradiotherapy following pancreaticoduodenectomy. Strahlenther Onkol


92. Song SH, Chie EK, Kim HJ, Kang CH, Kim YT, Kim JH, Park CI. Role of postoperative radiotherapy for

microscopic margin involvement in the squamous cell carcinoma of esophagus. Cancer Res Tr


93. Song C, Kim K, Chie EK, Kim JH, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW.

Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer

undergoing curative resection followed by adjuvant chemoradiationtherapy. Int J Radiat Oncol Biol

Phys. 2013;87(3):499-504 (Co-author)

94. Koh HK, Jeon W, Kim HJ, Wu HG, Kim K, Chie EK, Ha SW. Outcome analysis of salvage radiotherapy

for occult cervical cancer found after simple hysterectomy. Jpn J Clin Oncol. 2013;43(12):1226-1232

(Co-author)

95. Lee JH, Chie EK, Kim K, Jeong SY, Park KJ, Park JG, Kang GH, Han SW, Oh DY, Im SA, Kim TY, Bang

YJ, Ha SW. The influence of the treatment response on the impact of resection margin status after

preoperative chemoradiotherapy in locally advanced rectal cancer. BMC Cancer 2013,13(1):576


96. Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, Suh CO, Keum KC, Kim YB, Ahn SD, Kim SS, Ha

SW, Chie EK, Kim K, Shin HS, Kim JH, Lee HS. The role of postmastectomy radiation therapy after

neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: A multicenter,

retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65-72 (Co-author)

97. Lee JH, Kim JG, Oh ST, Lee WA, Chun HG, Kim DY, Kim TH, Kim SY, Baek JY, Park YW, Oh JH, Park

HC, Choi DH, Park YS, Kim HC, Chie EK, Jang HS. Two-week course of preoperative

chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional

clinical trial (KROG 11-02). Radiother Oncol 2014;110(1):150-154 (Co-author)

98. Noh JM, Park W, Suh CO, Keum KC, Kim YB, Shin KH, Kim K, Chie EK, Ha SW, Kim SS, Ahn SD, Shin

HS, Kim JH, Lee HS, Lee NK, Huh SJ, Choi DH. Is elective nodal irradiation beneficial in patients with

pathologically negative lymph nodes after neoadjuvant chemotherapy and breast-conserving

surgery for clinical stage II-III breast cancer? A multicentre retrospective study (KROG 12-05). Br J

Cancer 2014;110(6):1420-1426 (Co-author)

99. Lim YJ, Kim K, Chie EK, Han W, Noh DY, Ha SW. Treatment outcome of ductal carcinoma in situ

patients treated with postoperative radiation therapy, Radiat Oncol J. 2014;32(1):1-6 (Co-author)

100. Kim HY, Chie EK, Ahn YC, Kim K, Park W, Yoon WS, Huh SJ, Ha SW. Impact on loco-regional control

of radiochemotherapeutic sequence and time to initiation of adjuvant treatment in stage II/III rectal

cancer patients treated with postoperative concurrent radiochemotherapy. Cancer Res Tr


101. Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH,

Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH. Open versus

laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy

(COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial.

Lancet Oncol 2014;15(7):767-774 (Co-author)

102. Kim TY. Lee KH, Han SW, Oh DY, Im SA, Kim TY, Han W, Kim K, Chie EK, Park IA, Kim YT, Noh DY,

Ha SW, Bang YJ. A new isolated mediastinal lymph node or small pulmonary nodule arising during

breast cancer surveillance following curative surgery: Clinical factors that differentiate malignant

from benign lesions. Cancer Res Treat 2014;46(3):280-287 (Co-author)

103. Kwon J, Chie EK, Kim K, Kim HJ, Wu HG, Kim IH, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS,

Bang YJ, Ha SW. Impact of multimodality approach for patients with leptomeningeal metastases

from solid tumors. J Kor Med Sci 2014;29(8):1094-1101 (Corresponding author)

104. Kim K, Chie EK, Park HJ, Kim DG, Jung HW, Park SH, Kim IH. Exclusive radiotherapy for gliomatosis

cerebri: long-term follow-up at a single institution. Clin Transl Oncol 2014;16(9):829-833 (Co-author)

105. Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park JW, Seong J, Lee IJ, Jang HS, Kay CS, Kim CY, Chie

EK, Kim JH, Kim MS, Choi YM. Multicenter validation study of a prognostic index for portal vein

tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat. 2014;46(4):348-357 (Co-author)

106. Kim KS, Kim K, Chie EK, Kim YJ, Yoon JH, Lee HS, Ha SW. Prognostic stratification of brain metastases

from hepatocellular carcinoma. J Neurooncol. 2014;120(1):209-214 (Co-author)

107. Lee JH, Jang HS, Kim JG, Lee MA, Kim DY, Kim TH, Oh JH, Park SC, Kim SY, Baek JY, Park HC, Kim

HC, Nam TK, Chie EK, Jung JH, Oh ST. Prediction of pathologic staging with magnetic resonance

imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and

11-02. Radiother Oncol 2014;113(1):18-23 (Co-author)

108. Park HJ, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW.

Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery.

Anticancer Res. 2014;34(11):6685-6690 (Co-author)

109. Kim KS, Kim K, Chie EK, Kim YJ, Yoon JH, Lee HS, Ha SW. Post-treatment intracranial hemorrhage of

brain metastases from hepatocellular carcinoma. Radiat Oncol J 2015;33(1):36-41 (Co-author)

110. Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA. Radiosensitization with combined

use of olaparib and PI-103 in triple-negative breast cancer. BMC Cancer. 2015;15(1):89 (Co-author)

111. Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Joo I, Ha SW.

Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after

distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Tr 2015;47(2):274-281 (Co-author)

112. Korean Liver Cancer Study Group and National Cancer Center, Korea. 2014 KLCSG-NCC Korea

practice guideline for the management of hepatocellular carcinoma. Gut Liver 2015:9(3):267-317

(Co-author)

113. Korean Liver Cancer Study Group, National Cancer Center, Korea. 2014 Korean Liver Cancer Study

Group-National Cancer Center Korea practice guideline for the management of hepatocellular

carcinoma. Korean J Radiol 2015;16(3):465-522 (Co-author)

114. Kwon J, Kim BH, Kim K, Chie EK, Ha SW. Survival benefit of adjuvant chemoradiotherapy in patients

with ampulla of Vater cancer: A systematic review and meta-analysis. Ann Surg 2015;262(1):47-52

(Co-author)

115. Chie EK, Shin JH, Kim JH, Kim HJ, Kim IA, Kim IH. In vitro and in vivo radiosensitizing effect of

valproic acid on fractionated irradiation. Cancer Res Tr 2015;47(3):527-533 (First author)

116. Eom KY, Chie EK, Kim K, Chang JH, Koo TR, Ye SJ, Park JI, Park YK, Ha SW. Pilot study on inter-

fractional and intra-fractional movements using surface infrared markers and EPID for rectal cancer

patients treated in the prone position. Br J Radiol 2015;88(1052):20150144 (Corresponding author)

117. Lee JH, Kim DY, Kim SH, Cho HM, Shim BY, Kim TH, Kim SY, Baek JY, Oh JH, Nam TK, Yoon MS,

Jeong JU, Kim K, Chie EK, Jang HS, Kim JS, Kim JH, Jeong BK. Carcinoembryonic antigen has

prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative

chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of

KROG 14-12. Radiother Oncol 2015;116(2):202-208 (Co-author)

118. Sim JA, Shin JS, Park SM, Chang YJ, Shin A, Noh DY, Han W, Yang HK, Lee HJ, Kim YW, Kim YT,

Jeong SY, Yoon JH, Kim YJ, Heo DS, Kim TY, Oh DY, Wu HG, Kim HJ, Chie EK, Kang KW, Yun YH

Association between information provision and decisional conflict in cancer patients. Ann

Oncol 2015;26(9):1974-1980 (Co-author)

119. Koo T, Song C, Kim JS, Kim K, Chie EK, Kang SB, Lee KW, Kim JH, Jeong SY, Kim TY. Impact of lymph

node ratio on oncologic outcomes in ypStage III rectal cancer patients treated with neoadjuvant

chemoradiotherapy followed by total mesorectal excision, and postoperative adjuvant chemotherapy.

PLoS One 2015;10(9):e0138728 (Co-author)

120. Yu JI, Choi DH, Huh SJ, Cho EY, Kim K, Chie EK, Ha SW, Park IA, Ahn SJ, Lee JS, Shin KH, Kwon Y,

Kim YB, Suh CO, Koo JS, Kim JH, Jeong BG, Kim IA, Lee JH, Park W. Differences in prognostic factors

and failure patterns between invasive micropapillary carcinoma and carcinoma with micropapillary

component versus invasive ductal carcinoma of the breast: Retrospective multicenter case-control

study (KROG 13-06). Clin Breast Cancer 2015;15(5):353-361 (Co-author)

121. Song S, Kim K, Chie EK, Kim S, Park HJ, Yi NJ, Suh KS, Ha SW. Locoregional recurrence after curative

intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy. Clin

Trans Oncol 2015;17(10):825-829 (Co-author)

122. Yard B, Chie EK, Adams DJ, Peacock C, Abazeed ME. Radiotherapy in the era of precision medicine.

Semin Radiat Oncol 2015;25(4):227-236 (Co-author)

123. Lim YJ, Koh J, Kim K, Chie EK, Kim B, Lee KB, Jang JY, Kim SW, Oh DY, Bang YJ, Ha SW. High ratio

of programmed cell death protein 1 (PD-1)+/CD8+ tumor-infiltrating lymphocytes identifies a poor

prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant

chemoradiotherapy. Radiother Oncol 2015;117(1):165-170 (Co-author)

124. Kim BH, Kim K, Chie EK, Kwon J, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW.

The prognostic importance of the number of metastatic lymph nodes for patients undergoing

curative resection followed by adjuvant chemoradiotherapy for extrahepatic bile duct cancer. J

Gastrointest Surg 2015;19(10):1833-1841 (Co-author)

125. Park Y, Kim KS, Kim K, Chie EK, Kim JH, Kim JS, Kim TH, Kim DY, Jang WI, Kim MS, Koo TR, Chang

AR. Nomogram prediction of survival in patients with brain metastases from hepatocellular

carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study. J Neuro-oncol

2015;125(2):377-383 (Co-author)

126. Lim YJ, Kim K, Chie EK, Kim B, Ha SW. Role of adjuvant radiotherapy in left-sided pancreatic cancer-

population-based analysis with propensity score matching. J Gastrointest Surg 2015;19(12):2183-

2191. (Co-author)

127. Yun YH, Jung JY, Sim JA, Choi H, Lee JM, Noh DY, Han W, Park KJ, Jeong SY, Park JW, Wu HG, Chie

EK, Kim HJ, Lee JH, Zo ZI, Kim S, Lee JE, Nam SJ, Lee ES, Oh JH, Kim YW, Kim YT, Shim YM. Patient-

reported assessment of self-management strategies of health in cancer patients: development and

validation of the Smart Management Strategy for Health Assessment Tool (SAT). Psychooncology

2015;24(12):1723-1730 (Co-author)

128. Song JH, Kim SH, Lee JH, Cho HM, Kim DY, Kim TH, Kim SY, Baek JY, Oh JH, Nam TK, Yoon MS,

Jeong JU, Kim K, Chie EK, Jang HS, Kim JS, Kim JH, Kang KM. Significance of histologic tumor grade

in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: A multi-

institutional retrospective study. Radiother Oncol 2016;118(2):387-92 (Co-author)

129. Ha HR, Oh DY, Kim TY, Lee K, Kim K, Lee KH, Han SW, Chie EK, Jang JY, Im SA, Kim TY, Kim SW,

Bang YJ. Survival outcomes according to adjuvant treatment and prognostic factors including host

immune markers in patients with curatively resected ampulla of Vater cancer. PLoS One

2016;11(3):e0151406 (Co-author)

130. Jung J, Yoon SM, Park HC, Nam TK, Seong J, Chie EK, Kim TH, Kim MS, Kim CY, Jang HS, Kim JH.

Radiotherapy for adrenal metastasis from hepatocellular carcinoma: a multi-institutional

retrospective study (KROG 13-05). PLoS One 2016;11(3):e0152642 (Co-author)

131. Koh HK, Shin KH, Kim K, Lee ES, Park IH, Lee KS, Ro J, Jung SY, Lee S, Kim SW, Kang HS, Chie EK,

Han W, Noh DY, Lee KH, Im SA, Ha SW. Effect of time interval between breast-conserving surgery

and radiation therapy on outcomes of node-positive breast cancer patients treated with adjuvant

doxorubicin/cyclophosphamide followed by taxane. Cancer Res Treat 2016;48(2):483-490 (Co-author)

132. Eom KY, Cho BJ, Choi EJ, Kim JH, Chie EK, Wu HG, Kim IH, Paek SH, Kim JS, Kim IA. The effect of

chemoradiotherapy with SRC tyrosine kinase inhibitor, PP2 and temozolomide on malignant glioma

cells in vitro and in vivo. Cancer Res Treat 2016:48(2):687-697 (Co-author)

133. Yard BD, Adams DJ, Chie EK, Tamayo P, Battaglia JS, Gopal P, Rogacki K, Pearson BE, Phillips J,

Raymond DP, Pennell NA, Almeida F, Cheah JH, Clemons PA, Shamji A, Peacock CD, Schreiber SL,

Hammerman PS, Abazeed ME. A genetic basis for the variation in the vulnerability of cancer to DNA

damage. Nat Commun 2016;7:11428 (Co-author)

134. Lee HY, Kim N, Goo JM, Chie EK, Song HJ. Perfusion parameters as potential imaging biomarkers

for the early prediction of radiotherapy response in a rat tumor model. Diagn Interv Radiol.

2016;22(3):231-40 (Co-author)

135. Lee SW, Kim YJ, Shin KH, Kim K, Chie EK, Han W, Im SA, Jung SY, Lee KS, Lee ES. A comparative

study of daily 3-Gy hypofractionated and 1.8-Gy conventional breast irradiation in early-stage breast

cancer. Medicine (Baltimore). 2016;95(19):e3320 (Co-author)

136. Park HJ, Kim K, Paik JH, Chie EK, Kim S, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ,

Ha SW. Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer

treated with curative resection followed by adjuvant chemoradiotherapy? Clin Transl Oncol.

2016;18(6):625-31 (Co-author)

137. Kwak YK, Kim K, Lee JH, Kim SH, Cho HM, Kim DY, Kim TH, Kim SY, Baek JY, Oh JH, Nam TK, Yoon

MS, Jeong JU, Chie EK, Jang HS, Kim JS. Timely tumor response analysis after preoperative

chemoradiotherapy and curative surgery in locally advanced rectal cancer: A multi-institutional study

for optimal surgical timing in rectal cancer. Radiother Oncol 2016;119(3):512-518 (Co-author)

138. Choi Y, Oh DY, Kim K, Chie EK, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Ha SW, Bang YJ. Concurrent

chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer:

A retrospective cohort study. Cancer Res Treat. 2016;48(3):1045-1055 (Co-author)

139. Park BK, Park JW, Han EC, Ryoo SB, Han SW, Kim TY, Chie EK, Jeong SY, Park KJ. Systemic

inflammatory markers as prognostic factors in stage IIA colorectal cancer. J Surg Oncol

2016;114(2):216-221 (Co-author)

140. Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Prognostic

significance of nodal ratio in patients undergoing adjuvant chemoradiotherapy after curative

resection for ampullary cancer. Am J Clin Oncol 2016;39(4):346-349 (Corresponding author)

141. Lee SW, Shin KH, Chie EK, Kim JH, Im SA, Han W, Noh DY, Lim HW, Kim TH, Lee KS, Lee ES, Sung

SY, Kim K. Accelerated whole breast irradiation in early breast cancer patients with adverse

prognostic features. Oncotarget 2016;11702 (Co-author)

142. Wee CW, Kim K, Chie EK, Yu SJ, Kim YJ, Yoon JH. Prognostic stratification and nomogram for survival

prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis.

Br J Radio 2016;89(1065):20160383 (Co-author)

143. Koh HK, Chie EK, Kim K, Jang JY, Kim SW, Oh DY, Im SA, Bang YJ, Ha SW. Outcome analysis of

chemoradiation in unresectable pancreatic cancer focusing on treatment sequencing strategy.

Anticancer Res. 2016 Oct;36(10):5455-5461. (Corresponding author)

144. Kim BH, Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ,

Ha SW. Phosphorylated akt expression as a favorable prognostic factor for patients undergoing

curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer. Am

J Clin Oncol 2017;40(2):158-162 (Co-author)

145. Kim BH, Kim K, Chie EK, Kwon J, Jang JY, Kim SW, Oh DY, Bang YJ Long-term outcome of distal

cholangiocarcinoma after pancreaticoduodenectomy followed by adjuvant chemoradiotherapy: a 15-

year experience in a single institution. Cancer Res Treat. 2017;49(2):473-483 (Co-author)

146. Lim YJ, Koh J, Kim K, Chie EK, Kim S, Lee KB, Jang JY, Kim SW, Oh DY, Bang YJ. Clinical implications

of cytotoxic T lymphocyte antigen-4 expression on tumor cells and tumor-infiltrating lymphocytes

in extrahepatic bile duct cancer patients undergoing surgery plus adjuvant chemoradiotherapy.

Target Oncol. 2017;12(2):211-218 (Co-author)

147. Kim BH, Kim K, Chie EK, Kwon J, Jang JY, Kim SW, Oh DY, Bang YJ. Risk stratification and prognostic

nomogram for post-recurrence overall survival in patients with recurrent extrahepatic

cholangiocarcinoma. HPB. 2017;19(5):421-428 (Co-author)

148. Jeon SH, Shin KH, Park SY, Kim JI, Park JM, Kim JH, Chie EK, Wu HG. Seroma change during magnetic

resonance imaging-guided partial breast irradiation and its clinical implications. Radiat Oncol.

2017;12(1):103 (Co-author)

149. Kim KS, Kwon J, Kim K, Chie EK. Impact of resection margin distance on survival of pancreatic cancer:

a systematic review and meta-analysis. Cancer Res Treat. 2017;49(3):824-833 (Co-author)

150. Kim E, Kim K, Chie EK, Oh DY, Kim YT. Chemoradiotherapy after gemcitabine plus erlotinib in patients

with locally advanced pancreatic cancer. J BUON. 2017;22(4):1046-1052 (Co-author)

151. Kwon J, Kim K, Chie EK, Kim BH, Jang JY, Kim SW, Oh DY, Bang YJ. Prognostic relevance of lymph

node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant

treatment. Eur J Surg Oncol. 2017;43(9):1690-1696. (Co-author)

152. Kim JI, Lee H, Wu HG, Chie EK, Kang HC, Park JM. Development of patient-controlled respiratory

gating system based on visual guidance for magnetic-resonance image-guided radiation therapy.

Med Phys. 2017;44(9):4838-4846. (Co-author)

153. Kim JI, Chun M, Wu HG, Chie EK, Kim HJ, Kim JH, Park JM. Gamma analysis with a gamma criterion

of 2%/1 mm for stereotactic ablative radiotherapy delivered with volumetric modulated arc therapy

technique: a single institution experience. Oncotarget. 2017;8(44):76076-76084. (Co-author)

154. Kim BH, Chie EK, Kim K, Jang JY, Kim SW, Oh DY, Bang YJ, Ha SW. Impact of radiation dose in

postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results

from a single institution. Oncotarget. 2017;8(44):78076-78085. (Corresponding author)

155. Sim JA, Chang YJ, Shin A, Noh DY, Han W, Yang HK, Kim YW, Kim YT, Jeong SY, Yoon JH, Kim YJ,

Heo D, Kim TY, Oh DY, Wu HG, Kim HJ, Chie EK, Kang KW, Kim JH, Yun YH. Perceived needs for the

information communication technology (ICT)-based personalized health management program, and

association among information provision, health-related quality of life (HRQOL), and decisional

conflict in cancer patients. Psycho-oncology. 2017;26(11):1810-1817. (Co-author)

156. Kim YJ, Koh HK, Chie EK, Oh DY, Bang YJ, Nam EM, Kim K. Change in carbohydrate antigen 19-9

level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with

concurrent chemoradiotherapy. Int J Clin Oncol 2017;22:1069-1075. (Corresponding author)

157. Kim E, Kim YJ, Kim K, Song C, Kim JS, Oh DY, Nam EM, Chie EK. Salvage radiotherapy for

locoregionally recurrent extrahepatic bile duct cancer after radical surgery. Br J Radiol.

2017;90(1080):20170308. (Co-author)

158. Lim YJ, Koh JM, Kim S, Jeon SR, Chie EK, Kim K, Kang GH, Han SW, Kim TY, Jeong SY, Park KJ, Wu

HG. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating

lymphocytes identified patients with poor prognosis in rectal cancer: A matched comparison analysis.

Int J Radiat Oncol Biol Phys. 2017;99(5):1216-1224. (Co-author)

159. Kim BH, Kwon J, Chie EK, Kim K, Kim YH, Seo DW, Narang AK, Herman JM. Adjuvant

chemoradiotherapy is associated with improved survival for patients with resected gallbladder

carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25(1):255-264.


160. Yun YH, Jung JY, Sim JA, Lee JM, Noh DY, Han W, Park KJ, Jeong SY, Park JW, Wu HG, Chie EK, Kim

HJ, Jung KH, Zo JI, Kim S, Lee JE, Nam SJ, Lee ES, Oh JH, Kim YW, Kim YT, Shim YM. Development

and validation of the smart management strategy for health assessment tool-short form (SAT-SF) in

cancer survivors. Qual Life Res. 2018;27(2):347-354. (Co-author)

161. Kim BH, Kim E, Kim K, Jang JY, Kim SW, Oh DY, Chie EK. The impact of perioperative CA19-9 change

on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic

cholangiocarcinoma. J Surg Oncol. 2018;117(3):380-388. (Corresponding author)

162. Lee JH, Chie EK, Jeong SY, Kim TY, Kim DY, Kim TH, Kim SY, Baek JY, Hang HJ, Kim MJ, Park SC, Oh

JH, Kim SH, Lee JH, Choi DH, Park HC, Kang SB, Kim JS. Redefining the positive circumferential

resection margin by incorporating preoperative chemoradiotherapy treatment response in locally

advanced rectal cancer, a multicenter validation study. Cancer Res Treat. 2018;50(2):506-517.


163. Chun SJ, Jeon SH, Chie EK. A case report of salvage radiotherapy for a patient with recurrent gastric

cancer and multiple comorbidities using real-time MRI-guided adaptive treatment system. Cureus

2018;10(4):e2471. (Co-author)

164. Park Y, Kim K, Paik JH, Chie EK, Jang JY, Kim SW, Oh DY. High expression of MMP-9 is associated

with better prognosis in extrahepatic bile duct cancer patients. Eur J Surg Oncol. 2018:44(5):638-643.

(Co-author)

165. Wee CW, Kang HC, Wu HG, Chie EK, Choi N, Park JM, Kim JI, Huang CM, Wang JY, Ng SY, Goodman

KA. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal

cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of

acute toxicity. Jpn J Clin Oncol. 2018;48(5):458-466. (Co-author)

166. Chang JH, Shin KH, Ahn SD, Park HJ, Chie EK, Kim JH, Kim SS, Kim YB, Park W, Kim YJ, Shin HS, Kim

JH, Lee SY, Kim K, Park KR, Jeong BK, Kim JY, Kim S. Chest wall recurrence in pT1-2N0-1 breast

cancer patients after mastectomy without radiotherapy. Breast Cancer Res Treat. 2018;169(3):507-

512. (Co-author)

167. Son JM, Chun MS, Kang SH, Chie EK, Yoon JM, Choi CH, Park JM, Kim JI. Effect of low magnetic

field on dose distribution in the SABR plans for liver cancer. Prog Med Phys. 2018;29(2):47-52. (Co-

author)

168. Lee SW, Lee JH, Lee IK, Oh ST, Kim DY, Kim TH, Oh JH, Baek JY, Chang HJ, Park HC, Kim HC, Chie

EK, Nam TK, Jang HS. The impact of surgical timing on pathologic tumor response after short course

and long course preoperative chemoradiation for locally advanced rectal adenocarcinoma. Cancer

Res Treat. 2018;50(3):1039-1050. (Co-author)

169. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH,

Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH. Oncological benefits of

neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline

resectable pancreatic cancer: A prospective, randomized, open-label, multicenter phase 2/3 trial. Ann

Surg. 2018;268(2):215-222. (Co-author)

170. Kim KS, Kim HY, Kim K, Yi NJ, Suh KS, Chie EK. Postoperative chemoradiotherapy for R1 resected

intrahepatic cholangiocarcinoma. J Liver Cancer 2018;18(2):115-120 (Corresponding author)

171. Jang BS, Park HJ, Kim K, Jang JY, Kim SW, Oh DY, Chie EK. Role of adjuvant chemoradiotherapy for

duodenal cancer: An updated analysis of long-term follow-up from single institution. World J Surg.


172. Kim BH, Park HJ, Kim K, Han SW, Kim TY, Jeong SY, Park KJ, Chie EK. Novel graded prognostic

assessment for colorectal cancer patients with brain metastases. Int J Clin Oncol 2018;23(6):1112-

1120. (Corresponding author)

173. Kim BH, Chie EK, Kim K. ASO author reflections: Survival benefit of adjuvant chemoradiotherapy for

gallbladder cancer: The role of radiation therapy revisited. Ann Surg Oncol. 2018;25(s3):788-789.


174. Jeon SH, Song C, Chie EK, Kim B, Kim YH, Chang W, Lee YJ, Chung JH, Chung JB, Lee KW, Kang SB,

Kim JS. Delta-radiomics signature predicts treatment outcomes after preoperative

chemoradiotherapy and surgery in rectal cancer. Radiat Oncol. 2019;14(1):43. (Co-author)

175. Son J, An HJ, Choi CH, Chie EK, Kim JH, Park JM, Kim JI. Assessment of dose distributions according

to low magnetic field effect for prostate SABR. J Radiat Prot Res. 2019;44(1):26-31. (Co-author)

176. Park Y, Kim K, Park HJ, Jeong SY, Park KJ, Han SW, Kim TY, Chie EK. Results of re-irradiation for

pelvic recurrence in anorectal cancer patients. Br J Radiol. 2019;92:20180794. (Corresponding author)

177. Kim E, Kim K, Oh DH, Han SW, Kim TY, Jung SY, Park KJ, Kang GH, Chie EK. Differential effect of

concurrent chemotherapy regimen on clinical outcomes of preoperative chemoradiotherapy for

locally advanced rectal cancers. JBUON 2019;24(2):470-478. (Corresponding author)

178. Koh HK, Seo SY, Kim JH, Kim HJ, Chie EK, Kim SK, Kim IH. Disulfiram, a re-positioned aldehyde

dehydrogenase inhibitor, enhances radiosensitivity of human glioblastoma cells in vitro. Cancer Res

Treat. 2019;51(2):696-705. (Co-author)

179. Choi N, Kim JH, Chie EK, Gim J, Kang HC. A meta-analysis of the impact of neutrophil-to-lymphocyte

ratio on treatment outcomes after radiotherapy for solid tumors. Medicine (Baltimore).

2019;98(18):e15369. (Co-author)

180. Cho WK, Park W, Choi DH, Kim YB, Suh CO, Shin KH, Chie EK, Kim JH, Ahn SD, Kim SS, Kim K, Kim

JH, Ahn SJ, Lee SY, Lee J, Kim SW, Kwon J, Ahn KJ, Shin HS, Lee HS, Lee NK. Is tumor bed boost

necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast

conserving therapy? (KROG 12-05 and 16-16). Breast. 2019;45:43-47. (Co-author)

181. Kwon JH, Lee SC, Lee MA, Kim YJ, Kang JH, Kim JY, Lee HJ, Bae WK, Kim MJ, Chie EK, Kim J, Kim YH,

Chung HC, Rha SY. Behaviors and attitudes toward the use of complementary and alternative

medicine among Korean cancer patients. Cancer Res Treat. 2019;51(3):851-860. (Co-author)

182. Kim E, Kim K, Kim SH, Han SW, Kim TY, Jung SY, Park KJ, Koh J, Kang GH, Chie EK. Impact of mucin

proportion in the pretreatment MRI on the outcomes of rectal cancer patients undergoing

neoadjuvant chemoradiotherapy. Cancer Res Treat. 2019;51(3):1188-1197. (Corresponding author)

183. Kim YJ, Kim JH, Kim K, Kim HJ, Chie EK, Shin KH, Wu HG, Kim IH. The feasibility of spinal stereotactic

radiosurgery for spinal metastasis with epidural cord compression. Cancer Res Treat. 2019 Jan 29

[e-pub]. (Co-author)

184. Kang HC, Chie EK, Kim HJ, Kim JH, Kim IH, Kim K, Shin BS, Ma E. A phthalimidoalkanamide derived

novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous

recombination of DNA damage. Invest New Drugs. 2019 Feb 22 [e-pub]. (Co-author)

185. Jeon SH, Chie EK, Kim YJ, Lee KH, Lee HS, Kim MJ, Im SA, Kim JI, Kim TY. Targeted next-generation

DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response.

Int J Radiat Biol [in press]. (Corresponding author)

Documents

Name: Eui Kyu Chie · Radiotherapy for breast cancer patients treated with preoperative chemotherapy followed by surgery. 2007/05/11 Korean Society for Radiation Oncology Symposium,